Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

January 14, 2010

mondoBIOTECH holding AG announces today the terms of its planned share capital increase

NOT FOR DISTRIBUTION IN THE UNITED STATES (OR TO US CITIZENS), THE UNITED KINGDOM AND THE REPUBLIC OF ITALY. Stans, Switzerland - January 14, 2010. mondoBIOTECH holding AG announces today the terms of its planned share capital increase: The Company's share capital is planned to be increased out of authorized share capital by issuance of up to 304’131 fully paid-in registered common shares with a par value of CHF 0.10 each. In addition, the Company will give subscribers of new common shares the opportunity to purchase one option per each newly issued common share, entitling its holder to subscribe within an exercise period of 3 years for one new common share. The capital increase will be conducted by way of a rights offering to existing shareholders (the "Offering"). Under the terms of the Offering, existing shareholders will be allotted 10 tradable subscription rights for each listed common share and one subscription right for each non-listed voting right. The subscription ratio is 215:1, i.e. 215 subscription rights entitle to subscribe for one new common share at the subscription price expected to be announced on 22 January 2010 after close of trading. The subscription rights are expected to be traded on the SIX Swiss Exchange from 25 January 2010 until and including 5 February 2010. Ex-rights trading in the existing common shares is expected to begin on 25 January 2010. The exercise period for the subscription rights is expected to run from 25 January until 12 February 2010, 12:00 noon (CET). The first trading day of the new common shares on the SIX Swiss Exchange is expected to be 17 February 2010 (ticker symbol: RARE). The new common shares will be fully fungible with the existing common shares. The options will not be listed for the time being. The major shareholders of the Company, holding an aggregate of 73% of the voting rights in the Company, have decided to assign their subscription rights to Imperial Fund Ltd., one of the largest shareholders holding common shares of the Company, free of charge as an appreciation for Imperial Fund's great support to the Company in the past and the present. Imperial Fund Ltd. has committed to exercise, or cause other investors to exercise all of the subscription rights allotted and assigned to it in the Offering and to subscribe or cause such investors to subscribe for the corresponding number of new common shares. Accordingly, at least 65% of the common shares offered are expected to be placed with Imperial Fund Ltd. and/or investors referred by it. The offered shares will not be underwritten. Accordingly, the exact number of common shares to be issued depends on the total amount of subscriptions received from existing shareholders and/or acquirors of subscription rights in the Offering. The expected net proceeds from the Offering will be used to finance the further development of the Company’s product pipeline and therefore contribute to speed-up the process of making further medicinal product candidates available on the market.   The issue price of the new shares, the purchase price of the options and the strike price of the options are expected to be determined by the Board of Directors on 22 January 2010 after close of trading. Mondobiotech's share today closed at CHF 223.00. “With this capital increase we expect to pursue our financing strategy. The planned increase of the Company's capital base will allow us to broaden the development of our product pipeline and to prepare the Company to further enlarge its shareholder base” said Fabio Cavalli, CEO and member of the Board of Directors of mondoBIOTECH holding AG. About Mondobiotech Mondobiotech (mondoBIOTECH holding AG: SIX: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: Dr. Yvonne Gunsch-Wegmann, MBA Head of External Relations mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 - Stans - Switzerland T   +41 (0)840 200 010 F   +41 (0)41 611 09 34 M  +41 (0)79 414 39 33 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF MONDOBIOTECH HOLDING AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF MONDOBIOTECH HOLDING AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX LISTING RULES. This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your Download the Newsletter in the pdf format

Back to list